- Home
- WTM vs PRAX Comparison
WTM vs PRAX Comparison
Compare WTM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WTM
- PRAX
- Stock Information
- Founded
- WTM 1980
- PRAX 2015
- Country
- WTM Bermuda
- PRAX United States
- Employees
- WTM N/A
- PRAX N/A
- Industry
- WTM Property-Casualty Insurers
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- WTM Finance
- PRAX Health Care
- Exchange
- WTM Nasdaq
- PRAX Nasdaq
- Market Cap
- WTM 4.4B
- PRAX 4.0B
- IPO Year
- WTM N/A
- PRAX 2020
- Fundamental
- Price
- WTM $1,901.43
- PRAX $161.33
- Analyst Decision
- WTM
- PRAX Strong Buy
- Analyst Count
- WTM 0
- PRAX 12
- Target Price
- WTM N/A
- PRAX $210.25
- AVG Volume (30 Days)
- WTM 26.5K
- PRAX 1.6M
- Earning Date
- WTM 11-06-2025
- PRAX 11-05-2025
- Dividend Yield
- WTM 0.05%
- PRAX N/A
- EPS Growth
- WTM N/A
- PRAX N/A
- EPS
- WTM 54.05
- PRAX N/A
- Revenue
- WTM $2,603,700,000.00
- PRAX $7,463,000.00
- Revenue This Year
- WTM N/A
- PRAX N/A
- Revenue Next Year
- WTM N/A
- PRAX $44.43
- P/E Ratio
- WTM $23.74
- PRAX N/A
- Revenue Growth
- WTM N/A
- PRAX 364.98
- 52 Week Low
- WTM $1,648.00
- PRAX $26.70
- 52 Week High
- WTM $2,023.00
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- WTM 54.77
- PRAX 57.12
- Support Level
- WTM $1,888.00
- PRAX $154.46
- Resistance Level
- WTM $1,929.20
- PRAX $175.96
- Average True Range (ATR)
- WTM 32.84
- PRAX 13.47
- MACD
- WTM -6.57
- PRAX -5.54
- Stochastic Oscillator
- WTM 45.89
- PRAX 14.53
About WTM White Mountains Insurance Group Ltd.
White Mountains Insurance Group Ltd is engaged in the business of making opportunistic and value-oriented acquisitions of businesses and assets in the insurance, financial services, and related sectors, operating these businesses and assets through its subsidiaries and, if and when attractive exit valuations become available, disposing of these businesses and assets. The company conducts its business in five areas: property and casualty insurance and reinsurance, municipal bond reinsurance, capital solutions for asset and wealth management firms, property and casualty insurance distribution, and other operations.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.